快要 飞的 《药股》 讨论区

葉芬

http://biomedreports.com/article ... el-sci-cvm-dip.html

Buying the Cel Sci (CVM) Dip
Written by Vinny Cassano   
Monday, 05 October 2009 00:00


As CVM dropped to nearly $1.50, I couldn't resist adding to my holdings of the stock on Monday morning - even though it's a big 'average up' for me.

There's too much news due to be released in the fourth quarter of this year regarding Multikine and LEAPS for me to be comfortable with passing up the opportunity to add shares now.

Aside from any updates on the LEAPS trial, the fact that the Centers for Disease Control and Prevention added Cel Sci to the list of "vaccine and biologics manufacturers and distributors" could be an indicator that the FDA has signed off on Cel Sci's Baltimore manufacturing facility and an official announcement is pending. Once the FDA clears the facility I would expect to hear the announcement of a start date for the long-awaited Multikine Phase III trial.

Cel Sci, after already trading for five times its value at the beginning this year, still has quite a bit of room to move higher, if all goes according to plan over the next few months.

After seeing the news that the company has been added to the CDC's vaccine manufacturer list, it's hard not to get the feeling that there will be more news to come.

Disclosure:  Long CVM.

Vinny Cassano also authors the popular investing website VFC's Stock House.

UPDATE: The company released a letter to the shareholders late into the trading day Monday. In it, Ken S. Rosenthal, Ph.D., Professor, Microbiology, Immunology and Biochemistry, Northeastern Ohio Universities Colleges of Medicine and Pharmacology, to help explain in layman's terms the course of the H1N1 disease and why it can be so dangerous. Dr. Rosenthal also explained some of the science behind Cel-Sci's FDA fast tracked H1N1 flu treatment candidate:

CEL-SCI's dendritic H1N1 treatment, being developed as a treatment for H1N1 hospitalized patients, utilizes the unique LEAPS vaccine technology to convert an individual's white blood cells into cells targeted to killing influenza. The treatment is based on CEL-SCI's L.E.A.P.S. technology. LEAPS vaccines are small proteins that combine a piece of an influenza protein with a small activator protein. The combined protein activates the dendritic cell, a white blood - cell, which presents the influenza protein to the T cell and then tells that T cell with a focused, controlled amount of cytokine, to grow and make the cytokines necessary to activate protective T cell immune responses including killer T cells. This unique action promotes the production of inducer cytokines without the tissue damage and flu-symptom promoting cytokines (pro-inflammatory cytokines), tumor necrosis factor alpha or interleukin 1. This helps prevent or get around the issue of cytokine storm in which the production of too many pro-inflammatory cytokines contributes to the clinical decline and death of the patient. The activated dendritic cells seek out T cells that are specific for H1N1 influenza, present the influenza protein to them with the appropriate cytokines to get them excited, increase their numbers so that they can attack the infected cells with minimal peripheral damage.

The dendritic H1N1 treatment customizes the anti- influenza power of the LEAPS influenza technology. In short, the dendritic H1N1 treatment causes the maturation of monocyte white blood cells into dendritic cells that can direct and activate the subsequent immune response against H1N1 infected cells with minimal peripheral damage.

CHLaw

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        9,621.00  6:57am ET        Up 75.00 (0.79%)

雨若情

我一直玩澳洲啊。
我只是无意在这里看见你们。
4个月前我就一直在这里潜水。（因为要生了，在家得空）
随便讲几句，怎知道叶芬真的介绍cimb给我。
于是，我满月了就拿1w usd做本钱开户口咯。
看看有没有奶粉钱，旅行费。
所以，我都买小小的

[ 本帖最后由 雨若情 于 6-10-2009 07:29 PM 编辑 ]

TheMuppet

医药股还有其他的玩法。那就是在消息被炒热时购买put option。过去我都这样玩，风险就那几百块USD。买put option比你short来得安全多了。。又稳赚。

钻石与水

结果就赚了一大笔。。。哈哈

miku

cvm 怎么了？1.48.。。可以进吗叶姐？

wobushi

原帖由 TheMuppet 于 6-10-2009 08:51 PM 发表
医药股还有其他的玩法。那就是在消息被炒热时购买put option。过去我都这样玩，风险就那几百块USD。买put option比你short来得安全多了。。又稳赚。

有听说过, 请指教

雨若情

昨天cvm 1.55 buy进去了

现在还想进heb
我是菜鸟 切勿模仿

[ 本帖最后由 雨若情 于 6-10-2009 10:03 PM 编辑 ]

miku

1.35进的。。target1.45放。。

葉芬

原帖由 miku 于 6-10-2009 10:41 PM 发表
1.35进的。。target1.45放。。

你很幸運，一買就能買到這樣便宜價錢。 恭喜。
我剛剛再買進1.378 。。。慢了你一點。

再來個消息。。。

http://biomedreports.com/articles/most-popular/1683-reporters-inaccurate-articles-are-becoming-patient-safety-issue-claims-biomedical-company-ceo.html

                                                               
Wall Street reporter’s inaccurate reports are becoming patient safety issue claims biomedical company CEO                                                                                                               

Written by M.E.Garza

Monday, 29 June 2009 03:49

Responding to investor concerns that TheStreet.Com has continuedtargeting thriving small-cap biomedical companies with inaccuratearticles, BioMedReports has been repeatedly contacted by officials ofpublicly traded companies-- among them, Hoji Alimi who serves as CEO of Petaluma, California based Oculus Innovative Sciences (NASDAQ:OCLS).

Mr.Alimi’s breakthrough Microcyn® Technology- a water based, biocompatiblesolution used increasingly around the world to help prevent and treatinfections in chronic and acute wounds- has been gaining attention bothon Wall Street and in the national media due to its rapid killanti-microbial and healing properties.
A San Francisco bay area television station recently reported thatthe technology is a promising path to a major medical advance andearlier this month, Oculus shares rose after the company received anexpanded 510(k) label clearance from the U.S. Food and DrugAdministration (FDA) to market it’s Microcyn® Skin and Wound Cleanserwith preservatives as both a prescription and over-the-counterformulation. The new prescription product is indicated for use byhealth care professionals to manage the debridement of wounds such asstage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds,first- and second-degree wounds, grafted and donor sites.

Notlong after the announcement, TheStreet.Com’s biomedical columnist AdamFeuerstein leveled an accusation that Oculus “appeared to be skirtingU.S. drug laws by claiming that its wound-cleansing product containingcommon diluted bleach has drug-like therapeutic properties.”

Calls from angry and confused patients, doctors and investors floodedthe offices of the company and shares were negatively impacted.  Itcertainly wasn’t the first time, TheStreet.Com’s coverage has impacteda stock's price and its shareholders, but company officials becameconcerned when they heard reports that members of the medical communityand patients who use Microcyn® products were adversely affected by thereport.

“This is becoming a patient safety issue and puttingpublic safety at risk,” Alimi told BioMedReports in an exclusiverecorded interview. “It’s no longer [about] attacking a company and themarket potential and market cap. You’re damaging public safety.”

Alimi,was concerned enough to craft a letter to CNBC’s Jim Cramer whoco-founded TheStreet.com in 1996 and took the company public in 1999.

“copied the gentleman [Feuerstein] who had written the report,“explained the Iranian-born, Alimi. While the Oculus CEO made it clearthat he believed the publication and writer were entitled to theirconstitutionally protected opinion he felt that the publication hadfallen short of reporting the truth and science behind the technologyaccurately.

“When you haven’t done your due diligence and youdon’t understand the basic chemistry of our product [and] you makerecommendations like that you are putting patients’ safety at risk,”insists Alimi. “There has to be a level of integrity in the researchwritten and I think that’s really lacking in their case.”

Last month,Dr. William A. Carter, the CEO of Hemispherx Biopharma (NASDAQ:HEB)angrily reacted to slanted attacks and base-less reports by statingthat “Adam Feuerstein wouldn’t know good science if it bit him in theass.”

Investors across the internet have also lashed out againstFeuerstein’s coverage on message boards - many of them leveling threatsof physical violence while others have called for investigations byfederal authorities and even lawsuits. Feuerstein has responded to someof the anger by stating that “Carter's bluster [was] designed to divertattention away from the real matter at hand” and by clarifying to hisreader that he writes his columns and stories when he uncoversinformation that he thinks is important for investors to have.

Recently,Thomas Clarke, who had served as CEO of the financial news website,announced that he was leaving the publicly traded company “effectiveimmediately.”  It was reported that  Clarke’s abrupt departure cameless than a day after Jon Stewart’s  Comedy Central cable hit, TheDaily Show, aired tape of Jim Cramer explaining in a Street.com webcasthow he, as a hedge fund manager, manipulated value to serve somepublicly traded companies and investors at the expense of others.

Stewart’s show took Cramer, CNBC, and financial “journalism,” in general, to the cleaners but Feuerstein has insistedand written: “I don't make this job personal. I like to find goodstories to write about -- stories that hopefully help investors makesome money in biotech. (The best way to do that, sometimes, is to avoidbuying certain stocks)  If the stories are controversial, it's all thebetter, because those are usually the most fun.”

In the case ofOculus, the “story” has definitely not been perceived as “fun” andappears to fall short of fact- scientific or otherwise- according toAlimi.

Bleach is sodium hypochlorite which is anti-microbial at a high pH (pH scale of 8 and higher).

“Whenyou take that solution to a lower pH, you no longer have sodiumhypochlorite as your active [ingredient], you have Hypochlorus acid(HOCI)” explains Alimi. “It’s a different chemistry.  And Hypochlorusacid can be converted to different chemicals in a wound depending onhow it’s manufactured, so that is a significant difference in thechemistry of our product.”

Alimi points out that when aphysician uses bleach in a wound, he will surely kill the infection inthat wound, but he will also kill tissue and cause harm in the woundbed.  In addition, diluted bleach solutions have not shown any woundhealing impact- something that independent medical studies and trialshave attributed to Microcyn®.

Some feel that this type ofreporting can be directly blamed for TheStreet’s continued troubles anddecline in the current bear market.

As recently reported,the publication’s stock recently dropped below $2 per share, down from$9.50 per share a year ago. In recent years it had traded as high as$16 per, but it has also suffered with the decline in the media andadvertising markets as well as a major purge of subscriber newsletteroperations. Its success was initially tied closely to Mr. Cramer’spopularity, but the recent heavy criticism may finally be reflecting inthe company’s (NASDAQ:TSCM) stock price performance.

In astrange twist, many have noted that stocks which have been the subjectof slanted reports by Mr. Feuerstein, have just been added to theRussell 3000 index while TSCM itself has been booted as a financial services sector stock.

Anexcerpt of Mr. Almi’s interview with BioMedReports can be heard below.In it, he reacts to investors’ questions about litigation,TheStreet.Com’s coverage and whether or not Oculus has consideredissuing additional common shares.

[ 本帖最后由 葉芬 于 6-10-2009 11:17 PM 编辑 ]

miku

不是的叶姐，我的etrade不懂怎么搞的。。real time streaming quote是1.33的。。我按buy at market price怎么知道变成1.35，看回 streaming quote 还是1.33而已！！ 我很快就会放了。。

citc，heb有几次赚不少过5000usd但是没卖，等等等到现在ctic cut loss 输了2500usd，heb还hold着。。现在1.66.。亏了8000usd。。

SUNNY仔

原帖由 miku 于 6-10-2009 11:26 PM 发表
不是的叶姐，我的etrade不懂怎么搞的。。real time streaming quote是1.33的。。我按buy at market price怎么知道变成1.35，看回 streaming quote 还是1.33而已！！ 我很快就会放了。。

citc，heb有几次赚不少过5 ...

哇老...两张票帐面亏损超过一万美元..哪我的5000单位的CTIC四千多美元只是小巫见大巫...

jochen

ctic 看来 下定了。。。

只可以等 明年了。。。
很多 等不及的人 曾 市场 不怎么好。。。纷纷 跑了。。。。

雨若情

放心，我这只菜鸟要来陪你了

miku

heb 还在等carter说的秋天呀。。ctic早在1.28卖了。。那是亏2500usd。。不过后来买cvm，etfc早就赚回来多多了

我对heb还有期待。。

葉芬

大家昨晚有坐穩嗎？Roller Coaster Ride !
刺激吧 ， 只要安全帶綁好就沒問題了。

另一好消息。。


http://acr.confex.com/acr/2009/webprogram/Paper10996.html

Sunday, October 18, 2009: 9:00 AM - 11:00 AM
Hall D (Pennsylvania Convention Center)
Daniel Zimmerman, CEL SCI Corporation, Vienna, VA, Eyal Talor, CEL, Vienna, VA, Patricia Taylor, Northeastern Ohio colleges of Medicine, Rootstown, Sean O'Neill, Washington Biotech, Columbia, MD, Alison Bendele, BolderBiopath, Bolder, CO and Kenneth Rosenthal, Northeastern Ohio colleges of Medicine, Rootstown, OH
Presentation Number: 2
Poster Board Number: 2

Purpose: The collagen type II (bovine) (CIA) induced arthritis murine model is often used to evaluate treatments for rheumatoid arthritis (RA).  Following initial induction, the disease progresses into a more classical cell and cytokine mediated pathogenesis.  We will use this model to evaluate a new therapeutic vaccine for RA

Method: Male (7-8 week old) DBA/1J mice with CIA induced arthritis were either untreated or treated with the CEL-2000 L.E.A.P.S. experimental therapeutic vaccine or etanercept (Enbrel). CEL-2000 vaccine consists of 2 peptides of human origin, a segment of the beta 2 microglobulin molecule referred to as peptide J and a peptide (254-273) from human collagen Type II.  Disease was induced by 2 immunizations of bovine type II collagen on day 0 (in CFA) and day 21 (in ICFA).  The mice were scored daily for an Arthritic Index (AI) score.  Therapy was initiated when the mice (n=8) had a group mean AI score of 3.5 +/- 0.1 and range of 1-6.  CEL-2000 vaccine 33 or 100 nmole was administered on day 0 and 7 of therapy and etanercept 3 mg/kG was administered every other day for the 28 days unless otherwise noted. Mice were evaluated at least 3 times a week for A) footpad swelling and B) AI score.  At the termination of the study, tissue sections were evaluated for C) histopathological parameters including 1) inflammation, as evidenced by accumulation of eosinophils, basophils, neutrophils and macrophages, 2) cartilage destruction 3) bone resorption, and 4) pannus membrane formation in the synovial space. D) Sera, collected at the start of therapy and 10 days later, were evaluated for levels of 22 cytokines / chemokines, as measured by the RayBiotech protein array.

Results: By all four parameters there was a statistically significant (p < 0.05 or better depending on the day of therapy and parameter being considered) benefit of the CEL-2000 vaccine therapy and to a lesser extent for etanercept therapy.  CEL-2000 caused an increase in IL-12p70 and IL10 and reduction in disease associated serum levels of TNF-a, IL-17, IL-6, MCP-1 and IL-12p40.  A number of cytokine changes were also seen with Enbrel although to a lesser degree

Conclusion: CEL-2000 vaccine administered as a therapy arrested the progression of RA disease and its efficacy was demonstrated by reduction in disease parameters (AI) and in the reduction of serum levels of pro-inflammatory cytokines.

Keywords: collagen and vaccines

雨若情

很刺激。au的股票和my没什么差别。
          us的真的很像是做过山车。
我才进它就掉了 0.17

葉芬

原帖由 雨若情 于 7-10-2009 01:11 PM 发表
很刺激。au的股票和my没什么差别。
          us的真的很像是做过山车。
我才进它就掉了 0.17

不錯不錯 ，你的買進價 @ 1.55
還低過我的加碼後的價錢。

雨若情

我还想进cvm。。又想进heb
心大心小

葉芬

原帖由 雨若情 于 7-10-2009 04:56 PM 发表
我还想进cvm。。又想进heb
心大心小

HEB 要買的話，買少少就好。
CVM的勝算比較高。